KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Non-Current Deferred Tax Liability: 2012-2025

Historic Non-Current Deferred Tax Liability for Jazz Pharmaceuticals (JAZZ) over the last 14 years, with Sep 2025 value amounting to $629.0 million.

  • Jazz Pharmaceuticals' Non-Current Deferred Tax Liability fell 20.55% to $629.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $629.0 million, marking a year-over-year decrease of 20.55%. This contributed to the annual value of $676.7 million for FY2024, which is 51.16% down from last year.
  • According to the latest figures from Q3 2025, Jazz Pharmaceuticals' Non-Current Deferred Tax Liability is $629.0 million, which was down 7.78% from $682.1 million recorded in Q2 2025.
  • Over the past 5 years, Jazz Pharmaceuticals' Non-Current Deferred Tax Liability peaked at $1.9 billion during Q4 2021, and registered a low of $109.9 million during Q1 2021.
  • Moreover, its 3-year median value for Non-Current Deferred Tax Liability was $791.8 million (2024), whereas its average is $827.8 million.
  • As far as peak fluctuations go, Jazz Pharmaceuticals' Non-Current Deferred Tax Liability spiked by 1,011.84% in 2022, and later slumped by 51.16% in 2024.
  • Over the past 5 years, Jazz Pharmaceuticals' Non-Current Deferred Tax Liability (Quarterly) stood at $1.9 billion in 2021, then fell by 21.52% to $1.5 billion in 2022, then fell by 7.20% to $1.4 billion in 2023, then crashed by 51.16% to $676.7 million in 2024, then declined by 20.55% to $629.0 million in 2025.
  • Its Non-Current Deferred Tax Liability was $629.0 million in Q3 2025, compared to $682.1 million in Q2 2025 and $670.8 million in Q1 2025.